The Mystery of Chromosome 3p

Von Hippel-Lindau (VHL) disease and its associated tumors, such as CNS hemangioblastomas, pheochromocytomas, and clear cell renal cell carcinoma (ccRCC), are intricately linked to mutations and deletions on chromosome 3p. This chromosomal region, home to the VHL gene and other tumor suppressor genes, plays a critical role in tumor development and progression. The loss of chromosome 3p is a hallmark of ccRCC, occurring in over 90% of cases, and is often coupled with mutations in genes like PBRM1, SETD2, and BAP1, underscoring both VHL-dependent and VHL-independent pathways in tumorigenesis. In VHL-associated hemangioblastomas, advancements such as the HIF2α inhibitor belzutifan offer therapeutic promise, while pheochromocytomas linked to 3p mutations highlight the importance of genetic insights for early diagnosis and management. These findings emphasize the complexity of chromosome 3p’s role in cancer biology and the need for personalized, multidisciplinary approaches to treatment and surveillance. Understanding "The Mystery of Chromosome 3p" holds the key to unraveling the genetic and epigenetic mechanisms underlying these tumors and improving patient outcomes.